Compare AIP & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | STRO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.6M | 85.0M |
| IPO Year | 2021 | 2018 |
| Metric | AIP | STRO |
|---|---|---|
| Price | $16.01 | $11.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | $16.30 | ★ $18.29 |
| AVG Volume (30 Days) | ★ 650.7K | 125.6K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $65,931,000.00 | ★ $105,646,000.00 |
| Revenue This Year | $20.67 | $63.08 |
| Revenue Next Year | $20.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.45 | N/A |
| 52 Week Low | $5.46 | $5.23 |
| 52 Week High | $19.85 | $21.50 |
| Indicator | AIP | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 82.73 |
| Support Level | $14.96 | $8.49 |
| Resistance Level | $16.41 | $11.09 |
| Average True Range (ATR) | 1.02 | 0.87 |
| MACD | -0.20 | 0.03 |
| Stochastic Oscillator | 21.88 | 83.01 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.